Literature DB >> 12869145

Mucocutaneous findings in pediatric AIDS related to degree of immunosuppression.

Siriwan Wananukul1, Tawatchai Deekajorndech, Chitsanu Panchareon, Usa Thisyakorn.   

Abstract

The normal value of the absolute CD4-positive T-lymphocyte count is relatively high in normal infants and declines steadily until 6 years of age, whereas the CD4 percentage of the total lymphocyte count is constant. The immunologic categories according to the 1994 revised pediatric human immunodeficiency virus (HIV) classification, based on CD4-positive percentage of the total lymphocyte count, is classified into three categories: no evidence of suppression (> or =25%), moderate suppression (15-24%), and severe suppression (1-14%). Our objective was to determine the prevalence of mucocutaneous findings in pediatric acquired immunodeficiency syndrome (AIDS) related to the degree of immunosuppression. We prospectively examined 120 children less than 13 years of age who were born to HIV-seropositive women and developed definite HIV infection. The prevalence of mucocutaneous findings in those children who had severe, moderate, and no evidence of immunosuppression were 62%, 43%, and 20%, respectively. The mucocutaneous findings in patients in the moderate and severe suppression groups were significantly more common than in patients without evidence of immunosuppression (p < 0.001). In the moderate immunosuppression group, 11% had two mucocutaneous findings while 21% in the severe immunosuppression group had two or more mucocutaneous findings. The most common mucocutaneous finding was oral candidiasis (33%), which had a mean corresponding CD4 percentage of the total lymphocyte count of 11.3%. Herpes zoster was found in 6% of the patients (mean CD4 percentage of the total lymphocyte count = 13.5%). Chronic herpes simplex virus (HSV) stomatitis was found in 3% of the patients (mean CD4 percentage of the total lymphocyte count = 3%). Mucocutaneous manifestations are common in pediatric AIDS. The majority of these findings have an infectious etiology. The prevalence increases as the CD4-positive percentage of the total lymphocyte count decreases. More than one mucocutaneous finding can be found at the same time in patients with moderate or severe immunosuppression.

Entities:  

Mesh:

Year:  2003        PMID: 12869145     DOI: 10.1046/j.1525-1470.2003.20401.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  6 in total

1.  Red fingers syndrome and HIV infection.

Authors:  Vânia Oliveira Carvalho; Cristina Rodrigues Cruz; Leide Parolin Marinoni; Betina Werner; Tony Tanous Tahan; Hermênio Cavalcante Lima
Journal:  Arch Dis Child       Date:  2007-06       Impact factor: 3.791

2.  Skin disease among human immunodeficiency virus-infected adolescents in Zimbabwe: a strong indicator of underlying HIV infection.

Authors:  Sara Lowe; Rashida A Ferrand; Rachael Morris-Jones; Jon Salisbury; Nicholas Mangeya; Munyaradzi Dimairo; Robert F Miller; Elizabeth L Corbett
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

3.  Temporal trends in mucocutaneous findings among human immunodeficiency virus 1-infected children in a population-based cohort.

Authors:  Amy S Sturt; Andrew Anglemyer; David R Berk; Yvonne A Maldonado
Journal:  Pediatr Dermatol       Date:  2012-11-07       Impact factor: 1.588

4.  Severe Primary HSV-2 in a Perinatal HIV-Infected Woman with Advanced Immunosuppression.

Authors:  Lana Lee; Allison Agwu; Nancy Hutton
Journal:  Case Rep Med       Date:  2012-08-01

5.  The pattern of mucocutaneous disorders in HIV infected children attending care and treatment in Tikur Anbesa specialized hospital, Addis Ababa, Ethiopia.

Authors:  Yichalal Endayehu; Amha Mekasha; Firehiwot Daba
Journal:  BMC Dermatol       Date:  2013-10-25

6.  The pattern of mucocutaneous disorders in HIV-infected children attending care and treatment centres in Dar es Salaam, Tanzania.

Authors:  Millembe F Panya; Yassin M Mgonda; Augustine W Massawe
Journal:  BMC Public Health       Date:  2009-07-14       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.